The estimated Net Worth of James K Fong is at least $941 Mille dollars as of 24 January 2023. Mr Fong owns over 100,000 units of CTI BioPharma Corp stock worth over $941,406 and over the last 2 years he sold CTIC stock worth over $0.
Mr has made over 1 trades of the CTI BioPharma Corp stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 100,000 units of CTIC stock worth $95,000 on 24 January 2023.
The largest trade he's ever made was exercising 100,000 units of CTI BioPharma Corp stock on 24 January 2023 worth over $95,000. On average, Mr trades about 33,333 units every 0 days since 2023. As of 24 January 2023 he still owns at least 103,565 units of CTI BioPharma Corp stock.
You can see the complete history of Mr Fong stock trades at the bottom of the page.
James K. Fong is the Sr. VP & Chief Commercial Officer at CTI BioPharma Corp.
Mr Fong is 59, he's been the Sr. VP & Chief Commercial Officer of CTI BioPharma Corp since . There are 2 older and 3 younger executives at CTI BioPharma Corp. The oldest executive at CTI BioPharma Corp is Bruce K. Bennett Jr., 69, who is the Sr. VP Global Pharmaceutical Operations.
James's mailing address filed with the SEC is 3101 WESTERN AVENUE, SUITE 800, , SEATTLE, WA, 98121.
Over the last 21 years, insiders at CTI BioPharma Corp have traded over $80,110,449 worth of CTI BioPharma Corp stock and bought 9,566,060 units worth $25,487,533 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Advisors Llc Orbi Med Capit.... On average, CTI BioPharma Corp executives and independent directors trade stock every 26 days with the average trade being worth of $1,223,687. The most recent stock trade was executed by Adam R Craig on 24 January 2023, trading 85,317 units of CTIC stock currently worth $71,666.
cti was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. we strive to do business better than other biopharmaceutical companies. better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. a willingness to push the limits to achieve challenging goals is the essential attribute that sets cti employees apart.
CTI BioPharma Corp executives and other stock owners filed with the SEC include: